Bio Path Holdings Inc (BPTH)

Currency in USD
0.143
-0.014(-8.91%)
Closed·
Showing Bio Path historical data. For real-time data please try another search
Fair Value
Day's Range
0.1430.169
52 wk Range
0.1217.670
Key Statistics
Prev. Close
0.633
Open
0.157
Day's Range
0.143-0.169
52 wk Range
0.121-7.67
Volume
78.79K
Average Volume (3m)
390.62K
1-Year Change
-91.92%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BPTH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Bio Path Holdings Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Bio Path Holdings Inc Company Profile

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company’s lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.000

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.40 / -0.38
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BPTH Income Statement

People Also Watch

0.055
NCNA
-8.39%
7.8200
NUKK
-5.56%
2.9900
BBLG
-0.99%
1.480
PRFX
-0.67%
47.3000
TNXP
-4.88%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.